Four Colorado Companies Participate at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain in Park City, Utah
Four Colorado-based companies are participating at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain, March 2-4, at the Park City (UT) Marriott. Dorsey & Whitney, lead sponsor of the event, hosts venture capitalists and area companies to learn and explore bioscience opportunities in the Rocky Mountain Region. Co-sponsors include UV Partners, vSpring Capital and Wasatch Venture Fund.
Denver, CO, March 04, 2007 --(PR.com)-- Four Colorado-based companies are participating at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain, March 2-4, at the Park City (UT) Marriott. The announcement is made by Denise Brown, Executive Director, Colorado BioScience Association (CBSA) who says Dorsey & Whitney, lead sponsor of the event, hosts venture capitalists and area companies to learn and explore bioscience opportunities in the Rocky Mountain Region. Co-sponsors include UV Partners, vSpring Capital and Wasatch Venture Fund.
The following Colorado companies are participating in this “invitation-only” event (links to more information about each company are provided):
* Solix Biofuels – http://www.solixbiofuels.com
Solix Biofuels is a developer of massively scaleable photo-bioreactors for the production of biodiesel and other valuable bio-commodities from algae oil. Solix's management team believes it has made important breakthroughs in solving the two of the most important problems of our generation, namely our country's dependence on foreign oil and the acceleration of climate change. Through a partnership with Colorado State University (CSU) and its Engines & Energy Conversion Laboratory, the company has patent pending technology that builds upon 20 years of research (the Aquatic Species Program) originating at the National Renewal Energy Laboratory (NREL).
* Sierra Puenta, Inc. – http://fensters.com/Business%20Plan.htm
Sierra Puente, Inc., is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases of the brain. The company has created multiple reformulations of orally administered medications to be administered into the fluid around the brain for treatment of a platform of diseases including epilepsy, schizophrenia, bipolar disorder, and major depression. Sierra Puente was formed in 2005 to capitalize on the intellectual property of its Scientific Founders at the University of Colorado, Daniel Abrams, MD, Raymond Bunch, MD, Tom Anchordoquy, PhD and Karen Stevens, PhD.
* Apoplogic – http://www.apoplogic.com
ApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas. The company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D. Put most simply, ApopLogic is inducing rapidly dividing cells to commit suicide.
* Microphage – http://www.microphage.com
MicroPhage was founded and incorporated as a Delaware corporation in June 2002 by Jack Wheeler and Kent Voorhees Ph.D., to commercialize a bacterial detection technology licensed from the Colorado School of Mines. This platform technology utilizes a naturally occurring amplification process using lytic bacteriophage. Originally based upon the detection of the bacteriophage specific capsid protein with MALDI-TOF Mass Spectrometry, the company quickly demonstrated the reliability and ease of use of detecting bacteriophage with alternative methods including; lateral flow immunochromatography (LFI), enzyme linked Immunosorbant assay (ELISA), optical immunoassays (OIA) and polymerase chain reaction (PCR).
“Dorsey & Whitney’s efforts to bring investors to the Rocky Mountain region to become more familiar with some of our most promising start-ups is greatly appreciated. Their contacts in the investor community will prove to be invaluable to Colorado bioscience companies,” Brown explains. “The four Colorado companies that are presenting cover biotech, medical device, and biofuels – a great cross section of the activity here in Colorado.”
About Dorsey & Whitney LLP
Dorsey & Whitney LLP is among the largest law firms in the world. With 19 offices strategically located and approximately 650 lawyers and 850 support staff. According to the National Law Journal, which ranks firms by number of lawyers, Dorsey is the 63rd largest U.S. law firm. In The American Lawyer's "AmLaw 100" list, which ranks firms by gross revenues, Dorsey is number 68. Learn more about Dorsey & Whitney at http://www.dorsey.com.
The direct link to Dorsey’s “Venture Capital-Emerging Companies” practice area is http://www.dorsey.com/services/service_detail.aspx?page=overview&FlashNavID=
services_practice&serviceid=3438003.
About the Colorado BioScience Association
CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 300 members, CBSA actively works to promote the growth of the industry by working for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.
###
Contacts:
Denise Brown, Executive Director, Colorado BioScience Association http://www.cobioscience.com -- 303.592.4073, E-mail: dbrown@cobioscience.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations http://www.absolutelypr.com -- 303.984.9801, E-mail: maggie@absolutelypr.com
The following Colorado companies are participating in this “invitation-only” event (links to more information about each company are provided):
* Solix Biofuels – http://www.solixbiofuels.com
Solix Biofuels is a developer of massively scaleable photo-bioreactors for the production of biodiesel and other valuable bio-commodities from algae oil. Solix's management team believes it has made important breakthroughs in solving the two of the most important problems of our generation, namely our country's dependence on foreign oil and the acceleration of climate change. Through a partnership with Colorado State University (CSU) and its Engines & Energy Conversion Laboratory, the company has patent pending technology that builds upon 20 years of research (the Aquatic Species Program) originating at the National Renewal Energy Laboratory (NREL).
* Sierra Puenta, Inc. – http://fensters.com/Business%20Plan.htm
Sierra Puente, Inc., is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases of the brain. The company has created multiple reformulations of orally administered medications to be administered into the fluid around the brain for treatment of a platform of diseases including epilepsy, schizophrenia, bipolar disorder, and major depression. Sierra Puente was formed in 2005 to capitalize on the intellectual property of its Scientific Founders at the University of Colorado, Daniel Abrams, MD, Raymond Bunch, MD, Tom Anchordoquy, PhD and Karen Stevens, PhD.
* Apoplogic – http://www.apoplogic.com
ApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas. The company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D. Put most simply, ApopLogic is inducing rapidly dividing cells to commit suicide.
* Microphage – http://www.microphage.com
MicroPhage was founded and incorporated as a Delaware corporation in June 2002 by Jack Wheeler and Kent Voorhees Ph.D., to commercialize a bacterial detection technology licensed from the Colorado School of Mines. This platform technology utilizes a naturally occurring amplification process using lytic bacteriophage. Originally based upon the detection of the bacteriophage specific capsid protein with MALDI-TOF Mass Spectrometry, the company quickly demonstrated the reliability and ease of use of detecting bacteriophage with alternative methods including; lateral flow immunochromatography (LFI), enzyme linked Immunosorbant assay (ELISA), optical immunoassays (OIA) and polymerase chain reaction (PCR).
“Dorsey & Whitney’s efforts to bring investors to the Rocky Mountain region to become more familiar with some of our most promising start-ups is greatly appreciated. Their contacts in the investor community will prove to be invaluable to Colorado bioscience companies,” Brown explains. “The four Colorado companies that are presenting cover biotech, medical device, and biofuels – a great cross section of the activity here in Colorado.”
About Dorsey & Whitney LLP
Dorsey & Whitney LLP is among the largest law firms in the world. With 19 offices strategically located and approximately 650 lawyers and 850 support staff. According to the National Law Journal, which ranks firms by number of lawyers, Dorsey is the 63rd largest U.S. law firm. In The American Lawyer's "AmLaw 100" list, which ranks firms by gross revenues, Dorsey is number 68. Learn more about Dorsey & Whitney at http://www.dorsey.com.
The direct link to Dorsey’s “Venture Capital-Emerging Companies” practice area is http://www.dorsey.com/services/service_detail.aspx?page=overview&FlashNavID=
services_practice&serviceid=3438003.
About the Colorado BioScience Association
CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 300 members, CBSA actively works to promote the growth of the industry by working for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.
###
Contacts:
Denise Brown, Executive Director, Colorado BioScience Association http://www.cobioscience.com -- 303.592.4073, E-mail: dbrown@cobioscience.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations http://www.absolutelypr.com -- 303.984.9801, E-mail: maggie@absolutelypr.com
Contact
Colorado BioScience Association
Maggie Holben
303-984-9801
http://www.cobioscience.com
Maggie Holben
303-984-9801
http://www.cobioscience.com
Contact
Categories